The Next Frontier of Microbiome Science
Probiotics aren't just for your gut anymore. But what exactly is microbiome science,
and how can gut microbes affect your immune and lung health?
-
Microbiome (n): A community of commensal, symbiotic, and pathogenic organisms that share our body space.
Did you know there could be as many bacterial cells as there are human cells in a healthy human body? From the moment we take our first breath, the world around us is influencing our microbiome. And in turn, our microbiome is influencing our health.
-
Probiotics aren't just for your gut anymore.
People have been consuming live probiotics for gut health for centuries. In more recent decades, scientists have discovered that gut microbes also play important roles in other bodily systems – from immune response, to mental wellbeing, and even lung health!
-
Pioneers of the Gut-Lung Axis
The physician scientists behind ResBiotic were among the first to sequence the lung microbiome, and to examine the dynamic connections between gut and lung health. Founder Dr. Vivek Lal and Chief Medical Officer Dr. Amit Gaggar collaborated to better understand the role of the microbiome in regulating inflammatory pathways, and developed a blend that supports lung structure and function through the gut-lung axis.*
-
Our Flagship Formula
A proprietary combination of clinically studied probiotic strains and anti-inflammatory herbs, scientifically engineered to support lung structure and a healthy inflammatory response.*
-
Not All Probiotics Are Created Equal
The Highest Standards for Quality & Research
From strain validation and product formulation to testing, we’re collaborating with leading scientists and research partners to develop the first microbiome-based nutritional interventions for lung health.
-
Strain Development
Our strain bank is maintained with ResBiotic's own proprietary deposits, all backed by clinical (in vivo) and laboratory (in vitro) proof on concept and safety data. Our blend is formulated by optimizing indicative biomarker responses in tissue cells to better optimize support for the lungs. All of our strains have had their full genomes sequenced.
Strain Development
Our strain bank is maintained with ResBiotic's own proprietary deposits, all backed by clinical (in vivo) and laboratory (in vitro) proof on concept and safety data. Our blend is formulated by optimizing indicative biomarker responses in tissue cells to better optimize support for the lungs. All of our strains have had their full genomes sequenced.
-
Botanical Formulation
Each capsule contains ancient botanical extracts produced in a cGmP (Current Good Manufacturing Processes) environment by FDA-certified suppliers, specifically processed for extended stability and probiotic longevity. The combination of probiotics and botanical extracts combine to create a truly unique formulation, tailored toward lung support.
-
Production
ResBiotic's strain blend is produced via biofermentation at massive scale through optimizing fermentation temperature, pH, mother culture purity, and other factors. Each strain is enumerated and precision-blended to yield a consistent colony forming unit (CFU) count in each capsule, every time.
-
Quality
Every batch is analyzed for impurities, precision-blended according to current Good Manufacturing Practices (cGMP) from FDA-compliant manufacturing facilities, and sent to you from our FDA-registered fulfillment center. We only release to the public products that have met stringent quality, purity, and analytical testing requirements.
Meet the Scientists
-
Dr. C. Vivek Lal
Founder & CEO
-
Dr. Amit Gaggar
Chief Medical Officer
-
Dr. Thea Nicola
Director, Lab Operations
-
Dr. Namasivayam Ambalavanan
Advisor (Pediatric Lung Disease)
Endowed Professor & Virginia Walker Chair in Pediatrics, University of Alabama at Birmingham
-
Dr. Yvonne Huang
Advisor (Microbiome, Adult Lung Disease)
Associate Professor, Pulmonary & Critical Care Medicine & Director Huang Microbiome Lab, University of Michigan -
Dr. Nirmal Sharma
Advisor (Lung Transplant)
Assistant Professor Medical Director Lung Transplantation Program, Brigham & Women’s, Harvard University
-
Dr. Kent Willis
Advisor (Gut-Lung Axis, Mycobiome)
Assistant Professor & Director, Willis Lung Lab, University of Alabama at Birmingham -
Dr. Mike Wells
Advisor (Clinical Trials, Adult Lung Disease)
Associate Professor, Pulmonary & Critical Care Medicine, University of Alabama at Birmingham -
Dr. Casey Morrow
Advisor (Microbiome)
Professor Emeritus, Microbiome Resource Center & Cell Development & Integrative Biology, University of Alabama at Birmingham
Clinical Studies
Completed and ongoing studies of resB® Lung Support include
This was a randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took one resB® capsule twice daily (one in the morning, one at night) for one month.
Primary outcomes include testing safety measures. All participants tolerated the blend without adverse events.
Exploratory outcomes investigated changes in gut microbiota, serum MMP-9 and cytokines, CRP, lung function, oxygen levels, and changes in quality of life.
Completed 2022 – View Results
This is a multi-center randomized control trial in the United States with a dosing period of three months.
Primary outcomes center on change in quality of life.
Exploratory outcomes investigate clinical improvement markers (e.g., FEV1/FVC), gut and
lung microbiota, systemic and pulmonary biomarker changes (e.g., MMP-9, CRP,
cytokines, etc.)
This is a single-center randomized control trial in India with a dosing period of 14 days.
Primary outcomes center around pneumonia incidence and prognosis in elderly population in an acute care setting.